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ever, many governments are forsaking such tactics to focus on shorter-term quick
fixes. Whilst recognising that risks-sharing agreements represent an important
market access strategy, the objective of this research was to examine if the marked
expansion in number of risk-sharing agreements through 2007-2010 is still con-
tinuing, or if there is a gradual levelling off across the world.METHODS: Secondary
research was conducted examining reimbursement decisions around the world,
with a special focus on Australia, Belgium, Brazil, Canada, China, France, Germany,
Hungary, Italy, The Netherlands, New Zealand, Poland, Russia, Spain, Turkey, UK
and United States. This was supplemented by primary research with payors and
organisations through interviews in native languages to identify potential risk-
sharing agreements outside the public domain as well as general opinions.
RESULTS: Thirty-two new risk-sharing agreements were found in the period of
review (May 2011 - May 2012), which is roughly in-line with the rate found in
previous years. The number of new drugs with risk-sharing agreements attached to
them actually declined, and most new agreements are being negotiated for drugs
which already have one in place. The majority of agreements tend to be finance-
based, although new performance-based agreements continue to emerge, includ-
ing in emerging markets. The majority continue to focus on the oncology arena.
CONCLUSIONS: Although risk-sharing continues to be a routine part of market
access in many countries, there appears to be a notable “levelling off” of the rapid
expansion of this strategy in previous years. This is relatively unsurprising as it
reaches a natural plateau, but still notable against the background of ongoing
global austerity.
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IMPACT OF A FINANCIAL RISK-SHARING SCHEME ON BUDGET-IMPACT
ESTIMATIONS: A GAME-THEORETIC APPROACH
Hammerman A, Segev E, Gavious A, Greenberg D
Ben Gurion University of the Negev, Beer-Sheva, Israel
OBJECTIVES:As part of the process of updating the National List of Health Services
(NLHS) in Israel, both health-plans (‘payers’) and manufacturers provide estimates
on the expected number of patients that will utilize the drug. Currently, payers face
major financial consequences when actual drug utilization is significantly higher
than the allocated budget. We suggest a risk-sharing model that imposes a poten-
tial penalty on the two stakeholders; if the actual number of patients exceeds the
manufacturer’s prediction, the manufacturer will reimburse the payers by a rebate
rate of  from the deficit. In case of under-utilization, payers will refund the gov-
ernment at a rate of  from the surplus budget. Our study objective was to identify
the optimal early estimations of both ‘players’ prior to and after implementation of
the risk-sharing scheme. METHODS: Using a Game-Theoretic approach, in which
both players’ statements are considered simultaneously, we examined the impact
of risk-sharing within a given range of rebate proportions (, ), on players’ early
budget estimations. RESULTS: With no risk-sharing, manufacturers and health-
plans will choose to announce the smallest and highest number of patients, from
the cumulative distribution function of patients, respectively. When increasing “”
to be over 50%, manufacturers will announce a larger number and health-plans will
announce a lower number of patients than they would without risk-sharing, thus,
substantially decreasing the gap between their estimates. On the other hand, in-
creasing  changes players’ estimates only slightly. CONCLUSIONS: In reaction to
applying a substantial risk-sharing rebate “” on the manufacturer, both players
are expected to adjust their budget estimates towards an optimal equilibrium.
Since manufacturers do not benefit directly from the health-plans’ rebate to the
government, increasing  is a better vehicle for reaching the desired equilibrium
rather than increasing , as both players are substantially influenced by the man-
ufacturer’s rebate .
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RECENT GLOBAL INSIGHTS INTO RISK SHARING AGREEMENTS: A
COMPARATIVE ANALYSIS
Bruinsma IJ, Morawski J, Nijhuis T
Quintiles Consulting, Hoofddorp, The Netherlands
OBJECTIVES: To evaluate whether risk sharing agreements (RSA) are utlilised by
health technology assessment (HTA) agencies over the world. Similarities and dif-
ferences between appraisals where an RSA is applied will be assessed across the
different agencies. METHODS: Nine select HTA agencies across the globe
(MOHTLC, NICE, PBAC, SMC, TLV, INESSS, CADTH, NCPE, and AWMSG) were
scanned to determine what type of RSAs were adopted for drug appraisals. Only
single technology appraisals published between 2010 and April 2012 were included
in the search. Comparisons were made between the agencies to determine
whether any common trends were present, particularly for appraisals on the same
drug. RESULTS: In total 100 HTAs (74 treatments) were identified that included an
RSA across the 9 agencies. The number of RSAs identified per agency was as fol-
lows: MOHTLC (24 HTAs), NICE (23), PBAC (15), SMC (14), TLV (10), INESSS (7),
CADTH (6), NCPE (4), and AWMSG (2). Overall there was very little consistency
between agencies as to which treatments included an RSA. For the very few treat-
ments with an RSA fwith more than one agency, the type of agreement applied
between these agencies varied. RSAs identified in NICE submissions were often
elaborate whilst the remaining agencies usually applied simple discounts, price
reductions or cost agreements. Interestingly, all recently submitted oncology ther-
apies to INESSS were required to have a shared financial risk agreement for
recommendation. CONCLUSIONS: RSAs are applied by several HTA agencies from
around the world. There does not seem to be consistency in RSAs amongst the
different agencies. If an RSA is made for a particular treatment for one agency, this
does not mean an RSA will be applied by another agency for the same treatment.
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PAEDIATRIC USE MARKETING AUTHORISATION (PUMA): THE CHALLENGES OF
COST-EFFECTIVENESS MODELLING WHERE LIMITED CLINICAL TRIAL
INFORMATION IS AVAILABLE
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Paediatric use marketing authorisation (PUMA) was developed by the European
Medicines Agency to promote the development of paediatric formulations of prod-
ucts that are already authorised but are no longer covered by intellectual property
rights (patent, supplementary protection certificate). There are a number of aims of
which 2 are of interest here: ensure that medicines used to treat children are
subject to high-quality, ethical research and are appropriately authorised; and
achieve these objectives without subjecting the paediatric population to unneces-
sary clinical trials and without delaying the authorisation for other patients. In
September 2011 BUCCOLAM® was the first product to receive a PUMA for the treat-
ment of prolonged, acute, convulsive seizures. Products approved in this way are
likely to have less comparative data which makes both Pharmacoeconomic value
demonstration and assessment more challenging. In order to undertake cost-ef-
fectiveness analyses for BUCCOLAM to inform HTAs, de novoprimary data gather-
ing was required. This included: gathering expert views on treatment pathways,
downstream consequences of seizures and utilities (utilising a Delphi process);
gathering information on treatment pathways and the frequency and locale of
seizures (patient/carer surveys); and a cost-gathering exercise with hospitals. The
SMC and AWMSG were willing to accept the data gathered above in combination
with extensive sensitivity analysis which addressed the economic uncertainties
resulting from the limited clinical trial data. In other countries, where reimburse-
ment is linked to the strength of efficacy evidence it can be very difficult for a PUMA
product to demonstrate value. The PUMA process is relatively new and it may be
necessary for HTA bodies to review their requirements for interventions licensed
via this regulatory process and prepare an alternative pathway to assess their
value. In many cases this approach has been taken for orphan and ultra-orphan
diseases where the same data challenges may apply.
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WHY DO PATIENTS ENGAGE IN MEDICAL TOURISM?
Carrera P
University of Twente, Enschede, The Netherlands
Medical tourism is commonly perceived and popularly depicted as an economic
issue, both at the system and individual levels. The decision to engage in medical
tourism, however, is more complex, driven by patients’ unmet need(s), the nature
of services sought and the manner by which treatment is accessed. In order to
harness and promote the opportunities medical tourism offers, as well as address
and contain attendant threats, an informed decision is crucial. This paper aims to
enhance the current knowledge on medical tourism by isolating the types of deci-
sions that patients make – and based on the existing literature, proposing a theo-
retical sequence in opting for or against medical care abroad. It proposes a sequen-
tial decision-making process to engage in medical tourism, which includes
considerations of the required treatments, location of treatment, and the quality
and safety issues that are attendant to seeking care. Where patient involvement is
regarded as crucial in achieving the desired health outcomes and promoting the
efficient use of resources, the active role of the patient under medical tourism
should prove to be valuable. In consideration of the challenges and opportunities
that medical tourism offers, bringing forward scholarship on the globalization of
health care in general and of medical tourism in particular, calls for developing
empirical evidence on this increasingly popular and complex form of accessing and
provision of medical care.
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ADOPTION OF NEW TECHNOLOGIES IN TWENTY ESTABLISHED AND
EMERGING MARKETS
Hertz D, Marcarelli AD, Patel L, Garfield S
GfK Bridgehead, Wayland, MA, USA
OBJECTIVES: The purpose of this analysis was to evaluate drivers affecting market
access for new technologies in twenty established and emerging markets (Austra-
lia, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Italy, In-
dia, Japan, Norway, Poland, Russia, Spain, Turkey, the UK, Sweden, and
Switzerland). METHODS: Health care spend, government debt ratio, financing
structure and regulatory policy were examined relative to their impact on market
access. Comprehensive reviews of publicly available literature, data sources, poli-
cies and regulations were performed for each country of interest. RESULTS: En-
trants to markets without an official regulatory body face stiff competition from
non-standard or counterfeit comparator products. At the other extreme, some
countries require substantial country-specific clinical evidence for approval, mak-
ing them cost-prohibitive for smaller manufacturers . High government debt ratios
were found to be predictive of increased austerity measures, which broadly have a
negative impact on market access for new technologies, placing pressure on down-
ward pricing in countries that use national fee schedules. DRG-based systems were
found to be more receptive than markets that reimbursed inpatient facilities
through annual global payments. The likelihood of a medical device receiving an
HTA in any country is dependent on (1) regulatory requirements for market entry
and (2) the existence of device-focused HTAs, which are not as pervasive as HTAs
for pharmaceuticals. In countries where inpatient procedures are funded by global
payments, hospital level reviews are more likely than a national assessment for
medical device technologies. In countries where fee-for-service dominates device
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reimbursement methods, HTAs at the national level are more common.
CONCLUSIONS: Basic drivers of market access, such as health care spend, financ-
ing structure and regulatory policy create both independent and interdependent
mechanisms that support access to new device technologies. Consideration of
country level conditions and hurdles will inform device manufacturers’ differential
strategies to enter established and emerging markets.
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STAKEHOLDER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT (HTA)
OF NOVEL MEDICAL DEVICES
Hidefjall P
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HTA for medical devices follows the path of drugs in many countries. There are
however substantial differences that should be considered when evaluating med-
ical devices. Drummond (2009) describes six important differences. Medical de-
vices: 1) are often diagnostic therefore requiring to consider their related therapeu-
tic effects; 2) have faster product cycles often making trial results outdated; 3)
performance depend on users’ skills and complementary investments in training
and equipment; 4) innovation may cause a shift from one in-patient setting (oper-
ating room) to another (cathlab) or to an out-patient setting with substantial cost-
effects; 5) are manufacturer specific, making it difficult to draw conclusions about
product class effects; 6) innovation may be difficult to protect with patents thus
encouraging imitation with resulting falling prices. In addition to issues 1-6, regu-
latory approval of a device does not require the same level of evidence as for drugs.
Despite initial poor evidence, decisions on health care resource-use based on cost-
utility (QALY) need to be made throughout the product lifecycle. This can be
achieved by involving stakeholders in regular, timely data exchange for model
updating, considering issues 1-6 above. As medical devices directly affect several
stakeholders, their respective treatment costs from accounting systems can be
used (4). As product registries are continuously updated the improving perfor-
mance due to new devices and user learning is reflected (2-3). According to regu-
latory requirements manufacturers must evaluate their product performance and
notify competent authorities of adverse events. Such data should update cost-
utility evaluations relating to manufacturer specific patient morbidity (5). Further-
more as outcomes data are increasingly captured by devices directly or apps and
electronically transferred to electronic health records, the burden on manufactur-
ers to administrate registries may be lessened (2). As medical devices are regularly
procured in tenders, their product prices should be used (6). In turn HTA outcomes
should inform tenders.
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OPPORTUNITIES AND LIMITATIONS OF SUSTAINABILITY INDICES IN
SATISFYING THE NEEDS OF HEALTH TECHNOLOGY PURCHASERS SEEKING
OBJECTIVE AND UNBIASED INDICATORS OF ENVIRONMENTAL AND SOCIETAL
IMPACTS
Wright AJ, Froehlich HJ
PHMR Associates, London, UK
OBJECTIVE: To establish the extent to which existing sustainability indices provide
pertinent and transparent evidence of the environmental and social impacts of
health technology providers. METHOD: A search was undertaken to identify a
comprehensive list of sustainability indices for study. For each of these the follow-
ing criteria were identified; target constituency, specific environmental or social
domains being measured, criteria for inclusion, data sources and ranking or scor-
ing methodology. RESULTS: The majority of indices were found to be focused on
the needs of investors rather than purchasers. The indices either measured specific
environmental or social domains such as carbon efficiency, water risks and social
impacts, or provided a broader measure of sustainability by combining environ-
mental, social and governance issues together in a single metric. Incorporation
within an index often required inclusion in pre-existing non sustainability criteria
against which additional sustainability measures were applied. Data used within
the indexes reviewed were found to have been derived from publically available
sources such as websites and company reports, or from data submitted by the
organisations under evaluation to rating research groups. Few of the indices pub-
lished a level of methodological transparency that could provide sufficient visibil-
ity in order to understand how they are derived. CONCLUSION: There remains a
latent need among purchasers for a verifiable method of measuring sustainability
of providers. In order for a sustainability index to provide utility in the comparison
of health technology providers the following criteria must be met; The index
should be open to all Health Technology providers, methods used by the index to
measure performance should be transparent. None of the current sustainability
indexes reviewed fulfilled these criteria. Further study is needed to identify the
environmental and social domains of importance to purchasers and the best ap-
proach for deriving this data.
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FROM SCIENCE TO SERVICE: THE ONTARIO PATIENT REPORTED OUTCOMES OF
SYMPTOMS AND TOXICITY (ON-PROST) RESEARCH UNIT
Howell D, Perez Cosio A, Liu G, Rodin G, Hope A
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Research suggests that routine collection of Patient Reported Outcome Measures
(PROMs) can contribute to clinical decision-making and improve health, but their
systematic implementation in Ontario, outside the Edmonton Symptom Assess-
ment (ESAS), has not yet occurred. While ESAS is a valid symptom screening tool, it
does not allow customization to disease specific symptoms or toxicities nor does it
reflect the multidimensional impact of cancer on physical, emotional and social
health. Reaching consensus on a core set of PROMS for each of these domains is
critical to improving health and monitoring the impact of cancer. However, apply-
ing numerous PROMs is burdensome to patients and evaluators. We are now mov-
ing forward to make routine PROM data collection a reality in the cancer system.
On-PROST aims to improve the patient experience of cancer and the quality of care
through the routine collection of a standardized set of (PROMs) for use in clinical
care, and to advance the science of cancer treatment through research across the
cancer continuum. Based on initial consensus for the implementation of core
PROM data (PROMs-Cancer Core), we will develop a cohesive research agenda and
foster the development, standardization and implementation of core PROMs rele-
vant across cancer populations for research use and clinical practice. On-Prost
focuses on five cancer research areas: Health Services Research; Biomarker Re-
search; Radiation Oncology; Palliative and Supportive Care; and the PROMs-Cancer
Core items. We plan to develop national and international partnerships, and to
foster the development, standardization and implementation of core PROMs rele-
vant across cancer populations and for disease specific purposes for routine clinical
care and trials. Our goal is to foster common PROMs with multiple purposes, in-
cluding performance and impact of cancer reporting, that will help deliver person-
alized quality care and treatment, and will concretely impact on cancer control and
policy over the next five years.
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THE IMPACT OF THE GERMAN PHARMACEUTICAL MARKET REORGANISATION
ACT (AMNOG) ON THE GERMAN REFERENCE PRICE MARKET – TRENDS TWO
YEARS AFTER THE INTRODUCTION OF THE AMNOG
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With the introduction of the German Pharmaceutical Market Reorganisation Act
(German: “Arzneimittelmarktneuordnungsgesetz” (AMNOG)) in January 2011,
pharmaceutical entrepreneurs have to present a dossier to demonstrate the addi-
tional benefit of a new pharmaceutical at product launch in the German market.
Pharmaceuticals failing to demonstrate additional benefit against the standard of
care in the corresponding indication can be included in an existing reference price
group or even trigger the building of a new one. Top-selling reference price markets
with many newcomers or price-aggressive competitors are at risk of a repeated
examination through the federal joint committee (G-BA) in short intervals, result-
ing in a frequent updating of the reference price. This triggers a cascade, the so
called “Kellertreppeneffekt” (Race to the Bottom), which could result in a rapidly
decreasing reference price. One parameter of interest to assure an adequate secu-
rity of supply is the measure value 160, assuring that at least 20% of packages and
20% of prescriptions are available at a lower price than the new reference price. To
avoid the cascade, alternative, lower measure values, such as the measure value
100, can be applied. The measure value 100 is feasible for reference price groups
with a large amount of products which are free of patients’ copayment. Pharma-
ceuticals are normally free of patients’ copayment if the product price is 30% lower
than the corresponding reference price. The focus of our presentation is to analyze
the impact of the AMNOG on 10 top-seller reference price groups and to evaluate
further adjustments to the reference price level of these groups through varying
measure values. Furthermore, additional parameters of interest influencing the
reference price level will be considered.
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EFFECTIVE DEMAND FOR A HEALTH LITERATE HEALTH CARE SYSTEM -
EVIDENCE FROM IRISH SURVEY DATA
Coughlan D
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Health literacy (HL) research has mainly focused on the skills and abilities of indi-
viduals in the health care setting. For the past 20 years, most research has been
conducted in North America. However, HL is now gaining political support at Eu-
ropean Union level. This presentation is concerned with attitudes that nationally
representative survey respondents in Ireland have towards improving their health
by seeking a more health literate health care system. Two waves of the Survey of
Lifestyle, Attitudes and Nutrition (SLAN 1998 & 2002) were used in this analysis.
The primary focus of this study was to look across the socioeconomic gradient and
see whether Irish health policymakers should invest in HL as a health inequalities
or a public health issue. A secondary objective was to look at preventive health care
utilization (General health check-up, blood pressure check-up, blood cholesterol
check-up) using the HL variable as the main independent variable stratified by
gender and medical card eligibility.
The constructive dependent variable (termed ‘effective demand for a health liter-
ate health care system’) showed that 46% of respondents desired at least one at-
tribute on a health literate health care system. Various multivariate logistic regres-
sion models used social class grouping, medical card eligibility, level of education
and employment status as the main socioeconomic gradient variables. No discern-
ible trend emerged among the socioeconomic variables. This suggests that HL
should be viewed as a public health issue with a policy focus at a system level.
Consistently, females (OR 1.15; 95%:1.04 -1.28) were more likely than males to seek a
health literate health care system. However, males without a medical card with an effec-
tive demand for health literate health care system were more likely to get a general
check-up (OR 1.23; 95%:1.03 -1.47). The investment in making the system more user-
friendly would benefit all in society and not those stigmatized as having low literacy.
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CAN RISK MANAGEMENT PLANS (RMP) CONTRIBUTE TO HEALTH TECHNOLOGY
ASSESSMENT (HTA) AND KNOWLEDGE OF SAFETY IN EVERYDAY MEDICAL
PRACTICE?
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